A Comparative Study of Mefloquine and S-P as Prophylaxis Against Malaria in Pregnant HIV + Patients

A Comparative Study of Mefloquine and Sulphadoxine-pyrimethamine as Prophylaxis Against Malaria in Pregnant Human Immunodeficiency Virus Positive Patients

Randomized controlled single blind prospective comparative study.

This study is intended to be a randomized controlled single blind prospective comparative study conducted to compare the efficacy of three, monthly doses of sulphadoxine-pyrimethamine as intermittent preventive therapy with Mefloquine as-intermittent preventive therapy in HIV-infected pregnant women.

Inclusion Criteria:

• Pregnant HIV positive patients
• Gestational age 16 weeks and above
• No history of use of Mefloquine or Sulphadoxine
• Pyrimethamine four weeks prior to recruitment.

Exclusion Criteria:

• Anaemia packed cell volume less than 30%
• Pre -existing medical conditions- Diabetes Mellitus, -Hypertension
• Allergy to Sulphadoxine- Pyrimethamine or Mefloquine
• Non-consenting patients
• Multiple gestation
• Known psychiatric illness
• Known seizure disorder
• History of severe renal or hepatic disease